MedTrace Logo

Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis

NCT00883636 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 4

Last updated 2013-06-19

No results posted yet for this study

Summary

The objective of this study is as follows:

* Perform genetic analysis to define the prevalence of each of the known gene mutations in an unselected cohort of patients with focal segmental glomerulosclerosis (FSGS)
* Perform a comprehensive assessment of cardiovascular status to determine the incidence of any cardiac abnormalities in patients with FSGS
* Determine if patients with mutations in specific proteins are more likely to have cardiovascular abnormalities
* Initiate long-term follow up in all patients to determine whether cardiac prognosis is related to any specific genetic abnormality

Conditions

  • Focal Segmental Glomerulosclerosis
  • Nephrotic Syndrome
  • Steroid Resistant Nephrotic Syndrome
  • Chronic Kidney Disease

Interventions

OTHER

Cardiovascular Assessment

Measure of BNP, and Pro-BNP Complete 2 Dimensional Echocardiogram with Doppler evaluation including determination of, Left Ventricular mass, Ejection fraction, Midwall fractional shortening, velocity of early and late diastolic transmitral flow, and measurement of E/A ratio, Ratio of end-systolic wall stress to rate corrected velocity of circumferential fiber shortening.

OTHER

Renal Assessment

Complete a metabolic panel, CMP. Calculation of glomerular filtration rate, GFR, measure of urinary total protein, albumin and creatinine excretion in a first morning urine sample, 24 hour blood pressure monitoring,

OTHER

Genetic Evaluation

All patients will undergo genetic screening for all known podocyte gene mutations.

Sponsors & Collaborators

  • Northwell Health

    lead OTHER

Principal Investigators

  • Deborah Mensch, M.D. · Northwell Health

Eligibility

Min Age
6 Months
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2011-08-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00883636 on ClinicalTrials.gov